Loading...
Dear Readers,
As is true every year in HIV research, 2008 brought with it both dramatic progress and some significant failures. Certainly, our therapies have grown better and better, with virologic suppression now an achievable reality for virtually all patients, regardless of baseline stage of disease or degree of drug resistance. Our attempts at prevention, however, have continued to fail, most notably in the vaccine arena, where a once-promising adenovirus-based vaccine proved ineffective and possibly harmful. These failures have forced us to completely reconsider how we should approach HIV prevention, with a greater focus on antiretroviral therapy for both those with the virus and those at risk. In the next year, we can anticipate not on…